Satellos Bioscience Inc Stock Price, News & Analysis

Satellos (OTCQB: MSCLF) announced the first adult patient has been dosed in LT-001, an open-label long-term follow-up study of SAT-3247 in adult males with Duchenne muscular dystrophy.

The 11-month study will evaluate safety, MRI muscle composition, functional outcomes, and serum biomarkers in participants who completed Part D of the Phase 1b study. Results after the initial 3 months are anticipated in early 2026, then reported quarterly. The trial is underway at St Vincent’s Hospital, Melbourne, with plans to enroll up to 10 new participants in Australia and to open sites in the U.S., subject to regulatory and site approvals.

Satellos (OTCQB:MSCLF) reported new Phase 1a/b data showing SAT-3247 was safe and well tolerated and produced early functional gains in five adults with Duchenne muscular dystrophy after 28 days.

Key results: maximum grip strength increased mean 118.6% (dominant hand) and 97.9% (non-dominant hand), rising from ~2 kg to ~4 kg; predicted forced vital capacity improved mean 5.8%. No drug-related adverse events of moderate severity or higher and no dose-limiting toxicities were observed. Higher drug concentrations on Day 15 and higher baseline creatinine correlated with greater grip gains.

The five adult participants are invited to an 11-month open-label follow-up, and the company plans a Phase 2 randomized, double-blind, placebo-controlled study in ambulatory children with DMD with regulatory filings submitted.

Satellos Bioscience (OTCQB: MSCLF) announced it will present two scientific posters at the 30th Annual Congress of the World Muscle Society (WMS) in Vienna, Austria, from October 7-11, 2025. The presentations will feature new analyses from the Phase 1b study of SAT-3247, their investigational treatment for Duchenne muscular dystrophy.

The company's Chief Medical Officer, Dr. Wildon Farwell, will present late-breaking data from the Phase 1a/b study in healthy volunteers and adult Duchenne patients. Additionally, Dr. Ryan Mitchell, SVP of Medical & Scientific Affairs, will provide a clinical progress update on SAT-3247, which is designed to address deficits in muscle repair and regeneration.

Satellos Bioscience (OTCQB: MSCLF) has submitted an Investigational New Drug (IND) application to the FDA and parallel regulatory filings globally to initiate a Phase 2 clinical trial of SAT-3247 in children with Duchenne muscular dystrophy (DMD).

The three-month randomized, placebo-controlled study will evaluate safety, pharmacokinetics, and functional measures in ambulatory children, with the first patient enrollment expected by end of 2025. The company's Phase 1b study showed promising results, with patients experiencing doubled grip strength and 5% improvement in lung function.

Additionally, Satellos has initiated an 11-month extension study in Australia and received C$1.04 million through warrant exercises in Q3 2025.

Satellos Bioscience (OTCQB:MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in four major healthcare investor conferences this September.

The company will attend the Wells Fargo Healthcare Conference (Sept. 3, Boston), Cantor Fitzgerald Global Healthcare Conference (Sept. 5, New York), H.C. Wainwright Global Investment Conference (Sept. 9, New York), and Morgan Stanley Global Healthcare Conference (Sept. 10, New York). Two of these events will feature fireside chats that will be available via webcast on the company's investor relations website.

Satellos Bioscience (OTCQB: MSCLF) reported positive Phase 1b results for SAT-3247 in treating Duchenne muscular dystrophy (DMD). The trial demonstrated safety and an approximate doubling in grip strength in five adult DMD patients after 28 days of treatment.

The company plans to initiate a follow-up study in Q3 2025, with 3-month interim data expected by year-end. Satellos is also preparing for a global Phase 2 randomized trial in children with DMD, pending regulatory approvals.

Financially, Satellos ended Q2 2025 with $38.2 million in cash, reporting a net loss of $5.6 million ($0.03 per share) compared to $4.4 million ($0.04 per share) in Q2 2024. R&D expenses increased to $4.4 million from $3.6 million year-over-year.

Satellos Bioscience (OTCQB: MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in the Canaccord Genuity's 45th Annual Growth Conference. The event will take place on August 13-14, 2025, at the InterContinental Boston.

Management will deliver a presentation on Wednesday, August 13, from 12:30 to 12:55 p.m. ET in Abigail Adams C and will be available for one-on-one meetings. Investors can access the live webcast through the Events and Presentations page in the Investors section of Satellos' website, with a replay available after the event.

Satellos Bioscience (OTCQB: MSCLF) has appointed Dr. Wildon Farwell as Chief Medical Officer to advance their muscle disease therapeutic programs. Dr. Farwell joins from Dyne Therapeutics, where he served as CMO and brings significant expertise in neuromuscular disease drug development.

Dr. Farwell's notable achievements include building Dyne's development organization and leading their DMD and DM1 programs. At Biogen, he led the development of SPINRAZA®, the first approved treatment for spinal muscular atrophy, and initiated late-stage development of QALSODY® for ALS.

In his new role, Dr. Farwell will focus on advancing SAT-3247 into a global Phase 2 clinical trial for children with Duchenne muscular dystrophy (DMD). He succeeds Dr. Jordan Dubow, who will continue as a consultant and Clinical Advisory Board chair.

[ "Appointment of highly experienced CMO with proven track record in neuromuscular disease drug development", "New CMO has successful history of regulatory approvals, including SPINRAZA®", "Progress toward Phase 2 clinical trial for SAT-3247 in DMD treatment" ]

Satellos Bioscience (MSCLF) has elected two new board members, Dr. Iris Loew-Friedrich and Dr. Selwyn Ho, bringing significant expertise in clinical development and commercial strategy. Dr. Loew-Friedrich, former EVP and CMO at UCB, led global development and regulatory strategies resulting in multiple blockbuster therapy approvals. Dr. Ho brings extensive experience in commercial strategy and business development, having held senior roles at companies like Dermira, UCB, and Allergan. As CEO of Medigene AG, he led strategic partnerships and raised over $350M through IPO and private funding. Three board members - Dr. Rima Al-awar, William Jarosz, and Dr. William McVicar - did not seek reelection. The appointments come as Satellos advances its SAT-3247 program for Duchenne muscular dystrophy treatment.